Open Access

Optimizing treatment for the prevention of pre-eclampsia/eclampsia in Nepal: is calcium supplementation during pregnancy cost-effective?

  • Isabelle Feldhaus1,
  • Amnesty E. LeFevre1,
  • Chandra Rai2,
  • Jona Bhattarai2,
  • Deirdre Russo3,
  • Barbara Rawlins4,
  • Pushpa Chaudhary5 and
  • Kusum Thapa2Email author
Cost Effectiveness and Resource Allocation201614:13

DOI: 10.1186/s12962-016-0062-3

Received: 19 February 2016

Accepted: 2 December 2016

Published: 28 December 2016

Abstract

Background

In Nepal, pre-eclampsia/eclampsia (PE/E) causes an estimated 21% of maternal deaths annually and contributes to adverse neonatal birth outcomes. Calcium supplementation has been shown to reduce the risk of PE/E for pregnant women and preterm birth. This study presents findings from a cost-effectiveness analysis of a pilot project, which provided calcium supplementation through the public sector to pregnant women during antenatal care for PE/E prevention as compared to existing PE/E management in Nepal.

Methods

Economic costs were assessed from program and societal perspectives for the May 2012 to August 2013 analytic time horizon, drawing from implementing partner financial records and the literature. Effects were calculated as disability-adjusted life years (DALYs) averted for mothers and newborns. A decision tree was used to model the cost-effectiveness of three strategies delivered through the public sector: (i) calcium supplementation in addition to the existing standard of care (MgSO4); (ii) standard of care, and (iii) no treatment. Uncertainty was assessed using one-way and probabilistic sensitivity analyses in TreeAge Pro.

Results

The costs to start-up calcium introduction in addition to MgSO4 were $44,804, while the costs to support ongoing program implementation were $72,852. Collectively, these values correspond to a program cost per person per year of $0.44. The calcium program corresponded to a societal cost per DALY averted of $25.33 ($25.22–29.50) when compared against MgSO4 treatment. Primary cost drivers included rate for facility delivery, costs associated with hospitalization, and the probability of developing PE/E. The addition of calcium to the standard of care corresponds to slight increases in effect and cost, and has a 84% probability of cost-effectiveness above a WTP threshold of $40 USD when compared to the standard of care alone.

Conclusions

Calcium supplementation for pregnant mothers for prevention of PE/E provided with MgSO4 for treatment holds promise for the cost-effective reduction of maternal and neonatal morbidity and mortality associated with PE/E. The findings of this study compare favorably with other low-cost, high priority interventions recommended for South Asia. Additional research is recommended to improve the rigor of evidence available on the treatment strategies and health outcomes.

Keywords

Pre-eclampsia Eclampsia Maternal mortality Nepal Low-income countries Antenatal care Calcium Micronutrients Magnesium sulfate Cost-effectiveness

Background

Maternal and neonatal morbidity and mortality due to preventable causes contribute to a staggering proportion of the world’s burden of disease. In 2013, an estimated 289,000 women died from complications associated with pregnancy or childbirth; 27.1% due to hemorrhage, 14.0% hypertensive disorders, and 10.7% sepsis between 2003 and 2009 [1, 2]. Among children under five, 45% of deaths in 2015 occurred within the first 28 days of life with 28% of deaths due to pre-term causes [35]. In Nepal, an estimated 1500 maternal and 12,000 neonatal deaths occurred in 2015 [6, 7]. The country has seen reductions in maternal and under-five mortality by 76% and 71%, respectively, since 1990 [7, 8]. However, maternal deaths still make up nearly 10% of deaths among women of reproductive age and surveys show that the reduction in neonatal mortality, at only 34% in Nepal, greatly lags behind achievements in under-five and infant mortality [5, 8].

Eclampsia is the leading direct cause of maternal mortality in Nepal, occurring in 1 in 25 women and resulting in an estimated 21% of maternal deaths annually [9, 10]. The condition is also associated with adverse neonatal outcomes, including higher rates of neonatal intensive care unit admission and length of stay, small for gestational age, stillbirth, and mortality [1115]. Because termination of pregnancy is the definitive management of gestational hypertension and eclampsia, such complications remain the leading cause of provider-initiated preterm delivery globally [16, 17]. Magnesium sulfate (MgSO4) may significantly reduce the risk of recurring seizures to as low as 19%, and is used regularly across Nepal [10, 1823]. In some cases, cesarean sections are performed to ensure the safety of both mother and child [24]. Efforts toward the prevention of pre-eclampsia/eclampsia (PE/E) may contribute to reductions in maternal and perinatal mortality. In multiple clinical trials, low-dose calcium supplementation has been shown to reduce the risk of PE/E for pregnant women and preterm birth [14, 15, 22, 25, 26]. The World Health Organization (WHO) currently recommends that 1.5–2.0 g of calcium be taken daily during pregnancy for the prevention of PE/E, beginning at a gestational age of approximately 20 weeks [27].

Screening and early identification of women at risk for PE/E may enable appropriate antenatal care (ANC), management, and treatment. Evidence from high resource settings on the cost-effectiveness of PE/E screening is favorable [28, 29]. Findings from 33 countries included in the Magnesium Sulphate for Prevention of Eclampsia (Magpie) Trial suggest that prophylactic treatment of PE/E with MgSO4 is cost-effective for severe cases and when magnesium sulfate is available at little to no cost [30]. Analysis of prophylaxis strategies in the United States determined that universal prophylaxis with MgSO4 for all women with pre-eclampsia is cost-effective compared with treating only those with severe disease [31]. Meta-analyses assessing the cost-effectiveness of testing and treatment options for PE/E from the perspective of the United Kingdom’s National Health System suggest that providing calcium to all women without initial screening for PE/E is the most effective “test/treatment” option [29, 32]. However, the existing literature fails to conclusively determine whether calcium supplementation interventions are cost-effective in low-income settings.

From May 2012 through August 2013, the Ministry of Health and Population (MOHP) in Nepal, with technical support from the USAID-funded Maternal and Child Health Integrated Program (MCHIP) and Jhpiego, implemented a pilot program testing the feasibility of providing calcium supplements to pregnant women to prevent PE/E. The objective of the overarching study was to evaluate this pilot program and generate evidence informing future decisions for scale up. The primary aim of this model-based sub-study is to determine the incremental cost-effectiveness of calcium supplementation for PE/E prevention as compared to existing curative PE/E management in Nepal. Secondary objectives sought to explore the incremental cost effectiveness of three alternatives: (i) calcium supplementation in addition to MgSO4 (i.e. the existing standard of care), (ii) the existing standard of care, and (iii) no treatment for PE/E.

Ethical approval was obtained from Nepal Health Research Council and the Johns Hopkins University Bloomberg School of Public Health institutional review board.

Methods

Study setting and context

This pilot program was implemented in Dailekh District in the Mid-Western Region of Nepal based on the recommendations of a Technical Advisory Group formed to guide program implementation. Dailekh District, 650 km from Kathmandu, covers 1505 km2 with elevation ranges from 544 to 4168 m above sea level [33]. This mountainous district was chosen because its terrain represents the most common type of district in Nepal while having a greater population. As a result, it may most accurately illustrate the challenges associated with implementation nationwide. Dailekh had an estimated population of 264,616 in 2011, 51% of whom are women [33, 34].

The District Health Office provides preventive, curative, and promotional health services through 60 Health Facilities (HFs) [33]. Over 800 female community health volunteers (FCHVs) promote maternal and child health services across the district, corresponding to 1 FCHV per 1000 population. Utilization rates for key reproductive, maternal, newborn and child health services exceed national level estimates for most critical indicators. During pregnancy, 29% of women report receiving no ANC services at all compared to a national rate of 15.2% [33, 35]. Similar trends are reported for delivery careseeking with 59% of women delivering with the assistance of a skilled birth attendant, compared to 36% of women nationally [33, 35].

Program

Project activities began in May 2012 and spanned through August 2013. Startup activities included the development of training manuals on calcium supplementation, behavior change communication (BCC) materials, monitoring and evaluation tools, and initiation of training activities. Monitoring and evaluation tools were developed in line with the existing health management information system tools (i.e. calcium registers for ANC providers, calcium information added to existing FCHV registers, and reporting forms for village health workers and facility-level health providers). The supply of calcium supplements was purchased from Missionpharma India in 2012 and from Curex Pharmaceuticals Nepal in 2013.

To initiate district level activities, a half-day orientation was held for district level stakeholders. Four one-day training of district-level trainers with 95 attendees total followed. Sixty-one-day trainings at the health facility level trained all 268 ANC health workers in the district, while another 60 one-day trainings trained all 810 FCHVs. A full calcium supply and logistics support was provided to all health facilities. ANC health workers at government health facilities were trained to counsel pregnant women on the benefits of calcium supplementation during pregnancy and to distribute calcium during ANC visits. Health workers were also trained in the use of magnesium sulfate for treatment of severe PE/E and to perform PE/E screening using blood pressure measurements and urine protein tests, conducted upon each ANC visit. Health facilities were provided with urine collection bottles and dipsticks to ensure the availability of PE/E screening services for pregnant women during ANC visits. FCHVs were trained to promote ANC attendance and compliance with the recommended calcium regimen. Pregnant women attending an ANC visit were given a calcium supply for the remainder of their pregnancy. Women were typically provided with 300 calcium tablets if enrolled at ≤5 months gestational age and 100–200 tablets if enrolled at later gestational age. The recommended calcium intake was 1 g daily (2 tablets of 500 mg each), beginning at 16 weeks gestational age until delivery.

Comparators

The national standard drug for treatment of severe PE/E in Nepal is MgSO4, administered by health facility providers following screening for PE/E [23]. Program activities sought to expand the existing standard of care to include the provision of calcium supplements (i.e. MgSO4 + Calcium). In this analysis, we compare the costs and effects of the (i) MOHP calcium supplementation program in addition to the standard of care (i.e. MgSO4 + Calcium) against two hypothetical arms, (ii) MgSO4 treatment alone (i.e. standard of care in Nepal) and (iii) no treatment.

Calculating costs

Economic costs, presented here in 2014 US dollars (USD), were assessed using a societal perspective, inclusive of incremental costs to users and the government and/or health system. Program costs were obtained from financial records provided by implementing partners (MCHIP and Jhpiego), and adjusted according to the 2014 consumer price indices and market exchange rates. An annualized factor comprised of a 3% discount rate and WHO-CHOICE life expectancy estimates were used to annualize capital costs [36]. Program costs included capital (equipment, supplies, initial trainings), and recurrent (supervision, personnel costs, calcium supplements and MgSO4 treatment, PE/E screening supplies, and IEC materials) costs required to start-up and support ongoing implementation [21]. While the pilot program experienced calcium supply costs from two sources as a result of supply shortage during implementation, modeled costs were calculated assuming no future shortfall in calcium supply. To estimate costs to users and incremental costs to health system, additional data were drawn from the literature and a survey implemented by Jhpiego in three large government hospitals (Table 1). Based on survey findings, individual costs to hospitalize mothers, newborns, and PE/E cases were obtained, including costs of inpatient bed days, transportation, hospital personnel, cesarean section procedures, and other services.
Table 1

Total costs and inputs in 2014 USD

Indicator

Value

Distribution for PSA

Total fixed program costs

 Start-up costs

  Capital

$33,884.48

  Recurrent costs

$10,919.61

  Total

$44,804.09

 Implementation costs

  Recurrent costs

$72,827.94

  Blood pressure instrument

$24.25

  Total (not incl. variable costs, listed below)

$72,852.19

 Total program costs (per individual)

$0.44

 

Variable costs per individual

 Urine test (sample bottle + dipstick)

$0.07

Lognormal

 Calcium supply (per bottle, 100 tablets)

$0.69

Lognormal

 MgSO4 treatment regimen

$13.00 [21]

Lognormal

 Mean daily bed fee for maternal hospitalization

$4.21

Lognormal

 Other maternal hospitalization costs

$31.66

Lognormal

 Mean daily bed fee for newborn hospitalization

$8.25

Lognormal

 Other newborn hospitalization costs

$21.11

Lognormal

Mean indirect costs per individual

 Daily wage in district

$3.36 [42]

Lognormal

 Round trip transportation for hospitalization

$29.67 [41]

Lognormal

Mean duration of hospital stay

 Normal, healthy case

  Vaginal birth

1 day

  Cesarean section

4.3 days

  Live newborn

1 day

 PE/E case

  Vaginal birth

6 days

  Cesarean section

10 days

  Live newborn

7 days

Source: Jhpiego/MCHIP

Calculating effectiveness

Effects were calculated as disability-adjusted life years (DALYs) drawing from primary and secondary sources [37]. Estimates of the Years of Life Lost (YLLs) both to mothers and newborns were drawn from peer-reviewed literature, Nepal Demographic and Health Survey 2011, the Nepal Maternal Mortality and Morbidity Study 2008/2009, and primary data collected by Jhpiego on the calcium supplementation program (Table 2). Resulting probabilities for maternal and newborn mortality were adjusted according to the treatment received via each pathway through the model. Resulting effects were standardized to one million population.
Table 2

Background epidemiological and program data

Parameter

Base case

Low

High

Distribution for PSA

Maternal careseeking

 ANC, at least one visit

84.8% [35]

63.60%

100%

Beta

 Facility deliveries in government sector

26.0% [35]

19.5%

32.5%

Beta

Screening procedures

 Blood pressure

86.4% [35]

64.80%

100%

Beta

 Urine sample

55.9% [35]

41.9%

69.9%

Beta

 Blood sample

45.3% [35]

34.0%

56.63%

Beta

Eclampsia epidemiology

 Incidence of eclampsia

4.30% [9]

3.23%

5.38%

Beta

 Eclampsia as direct maternal cause of death

21.0% [10]

15.8%

26.3%

Beta

 Mean age of eclampsia patients

23.4 [38]

17.7 [38]

29.2 [38]

Treatment

 MgSO4 for PE/E management

68.9%a

51.7%

95.8%

Beta

 Cesarean delivery

55.31% [46]

41.5%

69.1%

Beta

Maternal risk ratios for PE/E

 Calcium supplementation

0.45 [15]

0.31 [15]

0.65 [15]

Beta

 MgSO4, standard regimen

0.19 [19]

0.14 [19]

0.24 [19]

Beta

 Cesarean delivery

0.55 [25]

0.41 [25]

0.69 [25]

Beta

Still birth rates

 Vaginal birth

1.37%a

1.03%

1.71%

Beta

 Cesarean delivery

0.43%a

0.32%

0.54%

Beta

 Vaginal birth among PE/E cases

14.3%a

10.7%

17.9%

Beta

 Cesarean delivery among PE/E cases

9.77%a

7.33%

12.2%

Beta

Disability-adjusted life years (DALYs)

 DALYs averted per individual (maternal)

24.9b

15.6c

31.8d

 DALYs averted per individual (newborn)

29.0b

16.4c

32.3d

Pilot Program Data, Dailekh District, 2013

 Maternal careseeking

  ANC, at least one visit

94.6%

71.0%

100%

Beta

 Calcium regimen compliance

  Full compliance

67.3%

50.5%

84.1%

  Partial or low compliance

32.7%

24.5%

40.9%

 Gestational age among women receiving calcium

  4–5 months (300 calcium tablets)

82.2%

61.7%

95%

  6–7 months (200 calcium tablets)

13.8%

25.6%

2.5%

  8–9 months (100 calcium tablets)

4.0%

12.8%

2.5%

 Screening procedures

  Blood pressure

98%

73.5%

100%

Beta

  Urine test

97%

72.8%

100%

Beta

aSource: Jhpiego/MCHIP

bDiscount rate 3% + no age weighting

cDiscount rate 6% + age weighting

dDiscount rate 3% + age weighting

The efficacy of MgSO4 treatment and cesarean section indicated as risk ratios were applied to outcomes accordingly. Those with partial or low compliance with the full calcium regimen (300 tablets) were conservatively assumed to experience no effects of calcium supplementation in the prevention of PE/E. Because the relevant mortality risk data were unspecified, it was assumed that the probability of maternal and newborn death was similar for at-home and facility deliveries. The average age of a maternal death was 23.4 years based on the mean age of eclampsia patients in Nepal, and the life expectancy for females in Nepal was 69 years of age [38, 39]. Newborn YLLs were determined using the mean life expectancy of males and females in Nepal, which is 68 years of age [39]. To generate years lost to disability (YLDs), disability weights for hypertensive disorders of pregnancy (0.00) [40] were used for mothers. The average age of onset used in the calculation of newborn YLDs was 0.0 years because mortality rates used in the model were associated with stillbirth.

Base case DALYs for mothers and newborns were discounted at a rate of 3% without age weighting. Incremental DALYs averted through the calcium supplementation program were calculated separately for mothers and newborns using relevant parameters, and summed for each study arm to generate a summary estimate of DALYs for each arm.

Data analysis

TreeAge Pro ©2014 was used to generate a decision tree analytic model to conduct incremental cost-effectiveness analyses (Fig. 1). Analyses were built around the possible pathways of a pregnant woman and newborns with respect to PE/E. The tree was divided into three primary branches attributed to each arm of the study: (i) calcium supplementation in addition to MgSO4 (i.e. the existing standard of care), (ii) the existing standard of care, and (iii) no treatment for PE/E. For individuals enrolled to receive calcium supplementation in addition to MgSO4, additional branches were included for attending at least one ANC visit, coverage of calcium distribution (i.e. gestational age at time of ANC visit), reported compliance with the full course of calcium, PE/E screening, onset of PE/E, hospitalization, MgSO4 treatment, cesarean section, and final health status of mothers and newborns (i.e. healthy/recovery or death). For the comparator arms reflecting (ii) existing standard of care and (iii) no treatment, similar sub-branches were used with the exception of those associated with calcium supplementation and MgSO4, as appropriate. The model represented a 1-year analytic time horizon consistent with the duration of the pilot program.
https://static-content.springer.com/image/art%3A10.1186%2Fs12962-016-0062-3/MediaObjects/12962_2016_62_Fig1_HTML.gif
Fig. 1

a Partial (two comparator arms shown) decision tree model of calcium supplementation program in Nepal. The segment in red is magnified. b Magnified inset: Decision tree model of calcium supplementation program for pregnant women in Nepal

Comparisons of costs and effects for each study arm were used to generate incremental cost effectiveness ratios (ICERs). Variations in individual parameters were tested within this framework using one-way and multi-way sensitivity analyses. The probabilities of compliance with the calcium regimen, risk ratio for the prevention of PE/E with calcium supplementation, and rates of screening, hospitalization, MgSO4 treatment, and cesarean section were varied. The costs associated with calcium supply, magnesium sulfate treatment, urine tests, and blood pressure testing were highlighted as costs of interest in these analyses as these were key commodities used in implementation of the program. These costs of interest as well as costs related to hospitalization were varied by 25% in sensitivity analyses with the exception of calcium supply, which had an upper bound of $1.42 USD per 100 tablets based on supplier prices (Table 1). Effects were varied from a base case of 3% discounting and no age weighting, to a high value under 3% discounting and age weighting and a low of 6% discounting and age weighting. A tornado diagram was generated to display variations in individual parameters in the univariate sensitivity analysis. Probabilistic sensitivity analyses explored the effect of simultaneous variations in multiple parameters.

Thresholds for determining cost-effectiveness

Overall findings on the cost per DALY averted for each option were evaluated according thresholds established in 2002 by the Commission on Macroeconomic and Health (CMH).1 Findings were additionally contextualized against estimates of the cost per DALY averted for other low cost high priority interventions stipulated by Disease Control Priorities, 2nd ed. and other examples of calcium and MgSO4 programs published in the literature. Cost-effectiveness acceptability curves were generated to approximate the proportion of iterations that were cost-effective for each study arm for willingness-to-pay (WTP) thresholds between $0 and $100 USD.

Results

Costs

Table 1 presents input parameters used to generate cost estimates. Start-up costs to provide calcium in addition to the existing standard of care were $44,804 and 1-year implementation costs were $72,852; these values correspond to a program cost per person per year of $0.44. Costs to users, which included transportation and daily wages lost, were $29.67 [41] and $3.36 [42], respectively. Variable costs for patient care included screening ($0.07), calcium supply ($0.69 per 100 tablets), the total cost of medicines and procedures associated with MgSO4 treatment ($13.00) [21], and daily bed fees for mothers ($4.21) and newborns ($8.25). Table 3 outlines the total costs associated with each condition considered in the model. Total inpatient costs to the health system were calculated according to the mean duration of hospital stay by health condition. The average duration of hospital stay for PE/E cases was estimated to be six days, and for those undergoing cesarean section, ten days. Newborns delivered by PE/E mothers remained hospitalized for an average of 7 days.
Table 3

Summary of total costs and effects by comparator

Condition

Total costs

Total effects

No treatment

$26.82

52.58

MgSO4

$26.98

52.68

MgSO4 + calcium

$29.29

52.71

Effects

All pregnant women attending at least one ANC visit were provided with a calcium supply corresponding to gestational age. ANC users at 4 or 5 months of pregnancy (82.2%) received 300 tablets, at 6 or 7 months (13.8%) received 200 tablets, and at 8 or 9 months (4.0%) received 100 tablets (Table 2). Of those women receiving calcium supplements, 67.3% reported adherence to the full course. The remaining 32.7% reported either completing a partial course or low compliance with the calcium regimen. Among women in the pilot program, the added probability of getting screened for PE/E risk through blood pressure measurement or urine testing was high (99.94%). The average risk ratio of PE/E with calcium supplementation during pregnancy is 0.45 (95% CI: 0.31, 0.65) [15]. This efficacy was applied in the model only for those women receiving and compliant with the full course (300 tablets) of calcium supplementation.

The proportion of births delivered in government facilities nationally (26%) was used as a proxy measure for the rate of hospitalization in Nepal since these data were not readily available, either nationally or from program data [35]. Among surveyed government hospitals, 68.9% of women received m MgSO4 treatment for severe PE/E management. This value was used to indicate the proportion of women receiving MgSO4 sulfate treatment. The efficacy of MgSO4 in the treatment of PE/E used in the analysis was a risk ratio of 0.19 [19]. The probability of a cesarean section for inpatients of government hospitals was determined by the rate of cesarean sections as a mode of delivery (55.3%) and their availability in government hospitals (71%) [10, 19]. The mortality rate used for pregnant women in the model was specific to eclampsia as a direct cause of maternal death (21%) [10]. Table 3 indicates the total effects associated with each condition considered in the model.

Incremental cost-effectiveness

Table 4 presents incremental cost-effectiveness ratios for MgSO4 vs. no treatment; MgSO4 + calcium vs. no treatment; and MgSO4 + calcium vs. MgSO4. Figure 2 depicts the cost-effectiveness plane showing mean estimates for 10,000 iterations of total costs and effects, while Fig. 3 present incremental cost-effectiveness scatter plots for each alternative considered. MgSO4 vs. no treatment was associated with a cost per DALY averted of $3.40 ($2.60–4.00) USD. MgSO4 + calcium vs. no treatment corresponded to a cost per DALY averted of $17.50 ($17.14–19.69) USD. When compared to the existing standard of care, the calcium program yields a cost per DALY averted of $25.33 ($25.22–29.50) USD.
Table 4

Summary of incremental cost-effectiveness ratios

Comparison

Deterministic calculations

Probabilistic analyses

Total incremental costs

Total incremental DALYs averted

Incremental cost per DALY averted

Total incremental costs

Lower bound

Upper bound

Total incremental DALYs averted

Lower bound

Upper bound

Incremental cost per DALY averted

Lower bound

Upper bound

MgSO 4 a vs.

no treatment

$0.16

0.05

$3.28

$0.17

$0.13

$0.20

$0.05

$0.05

$0.05

$3.40

$2.60

$4.00

MgSO4 + calcium vs.

no treatment

$2.47

0.13

$18.47

$2.45

$2.40

$2.56

$0.14

$0.14

$0.05

$17.50

$17.14

$19.69

MgSO4 + calcium vs.

MgSO 4 a

$2.31

0.08

$27.29

$2.28

$2.27

$2.36

$0.09

$0.09

$0.08

$25.33

$25.22

$29.50

aStandard of care

https://static-content.springer.com/image/art%3A10.1186%2Fs12962-016-0062-3/MediaObjects/12962_2016_62_Fig2_HTML.gif
Fig. 2

Cost-effectiveness plane showing mean estimates for 10,000 iterations of total costs and effects

https://static-content.springer.com/image/art%3A10.1186%2Fs12962-016-0062-3/MediaObjects/12962_2016_62_Fig3_HTML.gif
Fig. 3

Incremental cost-effectiveness scatter plot for comparison of three alternatives. Gray line indicates 95% confidence interval. a (i) calcium program vs. (ii) standard of care; b (i) calcium program vs. (iii) no treatment; c (ii) standard of care vs. (iii) no treatment

One-way sensitivity analyses revealed that incremental cost-effectiveness ratios were driven by four key parameters: (1) hospitalization for facility delivery, (2) cost of hospitalization, (3) cost of cesarean section, and (4) the probability of developing PE/E (Fig. 4). Probabilistic sensitivity analyses simulated the effect of simultaneous variations in multiple iterations (10,000). Findings suggest that the addition of calcium to the existing standard of care (MgSO4) is favored above a WTP threshold of ~$30 USD and has an 84% probability of being cost-effective above $40 USD (Fig. 5). When compared against a scenario of no treatment, MgSO4 + calcium is the preferred strategy for WTP thresholds of $25 or more. When considered independently of calcium supplementation, MgSO4 vs. no treatment is 100% cost-effective above WTP thresholds of $10 USD.
https://static-content.springer.com/image/art%3A10.1186%2Fs12962-016-0062-3/MediaObjects/12962_2016_62_Fig4_HTML.gif
Fig. 4

Tornado diagram (net benefits) illustrating the key drivers of cost-effectiveness. The base ICER is set at $26.84 per DALY averted in the diagram. Varying rate of facility delivery resulted in the greatest change in ICER, while varying hospitalization costs for PE/E cases resulted in the least change

https://static-content.springer.com/image/art%3A10.1186%2Fs12962-016-0062-3/MediaObjects/12962_2016_62_Fig5_HTML.gif
Fig. 5

Cost-effectiveness acceptability curves for three alternatives. a Calcium program (blue) vs. standard of care (red); b Calcium program (blue) vs. no treatment (red); c Standard of care (blue) vs. no treatment (red). The curves represent the percentage of iterations that were cost-effective (y-axis) for varying willingness-to-pay thresholds in 2014 US$ up to a ceiling $100. Findings suggest that the addition of calcium to the existing standard of care (MGSO4) is favored above a WTP threshold of ~$30 USD. When compared against a scenario of no treatment (B), MgSO4 + calcium is the preferred strategy for WTP thresholds of $25 or more. When considered independently of calcium supplementation, MGSO4 vs. no treatment is considered good value for money above WTP thresholds of $10 USD

Discussion

Study findings suggest that MgSO4 treatment of PE/E in Nepal is cost-effective when compared to no treatment at all. The addition of calcium supplementation increases costs and corresponds to a minor increase in effectiveness when compared against a scenario of no PE/E management. Despite the low incremental cost-effectiveness ratios across comparisons, findings suggest that for individuals only willing to pay $10 USD or less, MgSO4 is the preferred strategy for preventing PE/E. However, for individuals willing to pay more than $35 USD, calcium in addition to MgSO4 offers the best value for money.

When compared against alternative resource uses, MgSO4 + calcium and MgSO4 compare favorably against alternative low-cost high-priority interventions recommended for adoption in South Asia (Table 5). These interventions include increased primary care coverage, improved quality of comprehensive emergency obstetric care, improved overall quality and coverage of care, and neonatal packages targeted to families, communities, and clinics (Table 5). Beyond comparison with other health interventions, we compared study findings with those observed in other economic evaluations of PE/E treatment and prevention programs. In the Magpie Trial determined the incremental cost-effectiveness of prophylactic MgSO4 for 9996 women with pre-eclampsia from 33 countries; the incremental cost of preventing one case of eclampsia was $456 in low GNI countries and reserving MgSO4 prophylaxis for only severe cases of PE/E reduced this estimate to $263 [30]. Overall, the findings of this study fall well beneath the cost per DALY averted estimates observed in Magpie. However, limitations in available data, including those surrounding maternal and newborn health effects, may contribute to the disparities observed.
Table 5

Cost per DALY averted associated with low-cost high-priority interventions recommended for South Asia

Low-cost high-priority interventions recommended for South Asia

Mean cost per DALY averted (USD)

Childhood immunization

$8.00 [47]

 Additional coverage of traditional Expanded Program on Immunization

Full course calcium supplementation (82.2%) with 67.3% compliance in addition to MgSO 4 (68.9%) in Nepal

$25.33

HIV/AIDS

$9–126 [47]

 Voluntary counseling and testing

 Peer-based programs targeting at-risk groups

 School-based interventions that disseminate information to students

 Prevention of mother-to-child-transmission with antiretroviral therapy

Surgical services and emergency care

$6–212 [47]

 Surgical ward in a district hospital

 Staffed community ambulance

 Training of lay first responders and volunteer paramedics

Tuberculosis

$8–263 [47]

 Childhood vaccination against endemic TB

 Directly observed short-course chemotherapy

 Isoniazid treatment of epidemic TB

 Management of drug resistance

Using MgSO4 prophylaxis for only severe cases of pre-eclampsia in low GNI countries

$263.00 [30]

Maternal and neonatal care

$127–394 [47]

 Increased primary care coverage

 Improved quality of comprehensive emergency obstetric care

 Improved overall quality and coverage of care

 Neonatal packages targeted to families, communities, and clinics

Incremental cost of preventing one case of eclampsia using MgSO4 in low GNI countries

$456.00 [30]

The italicized text denotes the study program in Nepal and aims to contextualize our findings against those of alternative resource uses recommended by the Disease Control Priorities (2nd ed)

Beyond efforts to contextualize study findings with alternative programs and resource uses, we considered findings against the gross domestic product (GDP) of Nepal of $697 per capita in 2014 [44]—the threshold value for cost-effectiveness established by WHO CHOosing Interventions that are Cost Effective (WHO-CHOICE) and CMH [45]. The model demonstrates that calcium supplementation in addition to MgSO4 becomes more cost-effective with increased rates of PE/E. This suggests that the intervention would offer the greatest value for money in districts with higher incidence rates of the disease. If calcium supplementation is to be nationally adopted, targeting prevention efforts where incidence of PE/E is particularly high is recommended.

In 2005, the Government of Nepal established the Aama program, or Safe Delivery Incentive Program (SDIP), a demand-side financing scheme providing incentives to women to deliver in health facilities in order to improve mothers’ health outcomes and that of their child. In January 2009, user fees were removed for all types of delivery in government health facilities as well as selected accredited private hospitals. Under the Aama program, cash payments in the amount of NPR 500–1500 ($5.28–15.83 USD) depending on district terrain are made to women to pay for transportation to facilities for delivery [43]. The Aama program also provides incentives to the health facility for deliveries; participating health facilities are reimbursed NPR 1000–1500 ($10.55–15.83 USD) for normal deliveries, NPR 3000 ($31.66 USD) for complicated deliveries, and NPR 7000 ($73.87) for cesarean deliveries [43]. However, our model estimates these costs based on surveys conducted at three government hospitals. Survey findings indicated higher mean costs associated with transportation and hospitalization by type of delivery, thereby providing more conservative estimates of anticipated costs incurred by users and the health system.

The majority of cost-effectiveness drivers are associated with processes tied to hospitalization. Increases in the rates of hospitalization for facility delivery generally resulted in increased costs per DALY averted, suggesting that costs bring about greater impact on cost-effectiveness ratios than the health effects brought about by this intervention. Effectiveness data specific to the nuances of compliance to the calcium regimen and for women of different levels of risk of onset would provide better evidence in this regard.

Hospitalization for facility delivery is directly linked with the probability of receiving MgSO4 treatment and/or undergoing a cesarean section for PE/E. The cost of hospitalization and the additional cost of cesarean section procedures constituted the highest cost values incorporated into the model. As a significant proportion of overall costs, it corresponds that these cost factors have a greater impact on incremental cost-effectiveness ratios when varied. Still, with improved utilization of facilities for delivery, it may be possible to decrease the costs of hospitalization and cesarean section procedures and generate overall better health outcomes with PE/E hospitalization and treatment.

Increased use of calcium supplementation for the prevention of hypertensive disorders of pregnancy in the South Asia region may also result in reductions in the cost of calcium supply, further improving cost-effectiveness. A critical factor in determining whether or not mothers receive calcium supplementation and/or early treatment is ANC utilization. The Government of Nepal introduced the 4ANC incentive program in July 2009, providing cash payments to women NPR 400 upon following the ANC protocol of four ANC visits at specific gestation times, institutional delivery, and a postnatal visit [43]. Further increasing ANC and early ANC may serve to further increase use of and adherence to calcium. The combination of these efforts for the prevention of PE/E may culminate into a synergistic effect for optimal cost-effectiveness for Nepal and similar settings.

Limitations

This analysis was carried out retrospectively as part of the evaluation of a small-scale pilot program in the Dailekh District of Nepal. In the absence of a comparison area, the program is compared against hypothetical comparators of no calcium distribution to women during ANC. As extended observation of person-time spent administering calcium supplementation and counseling was not conducted as part of this pilot program evaluation, the time of health care providers to administer and counsel patients has not been included in this analysis. In the model, utilization of MgSO4 and cesarean delivery as a treatment for PE/E and their respective effects remained the same across arms regardless of case severity. Severity can also have considerable implications for morbidity and mortality that affect results. Differences in PE/E management according to case severity were not modeled because limited data exists describing differentiated effects for mothers and newborns based on PE/E severity.

We note that women attending at least one ANC visit may have a greater rate of hospitalization for various reasons. It is also possible that there is a greater hospitalization rate and treatment measures provided for mothers experiencing more severe PE/E. These nuances are not captured in the model due to lack of differentiated data. Beyond these parameters, the model relies upon secondary data to address gaps in primary data on mortality and many of the provider and users’ cost categories. Primary data on reported compliance with calcium regimens provided were drawn from household survey data provided by the program and may be vulnerable to recall bias.

Conclusions

Calcium supplementation for pregnant mothers provided with appropriate MgSO4 treatment holds promise for the cost-effective reduction of maternal and neonatal morbidity and mortality associated with PE/E. As modeled by the MOHP calcium supplementation pilot program in Nepal, such calcium interventions may be similarly cost-effective in other low-income settings. Additional research is recommended to further explore the implications of calcium on newborn outcomes and delivery at scale. Future research is needed to understand factors that may improve early initiation of ANC and increase rates of facility delivery. Efforts to deliver calcium at scale offer the potential to yield even greater cost-effectiveness given the high utilization of ANC—the delivery point of calcium supplementation.

Footnotes
1

The CMH stipulated that an intervention is highly cost effective (HCE) if it has a cost per DALY averted which is lower than the Gross Domestic Product (GDP) per capita. Interventions with a cost per DALY averted of less than 3 times the GDP per capita are deemed cost effective, while those with a DALY averted which is 3 times that of the GDP are considered cost ineffective. Considering costs according to these standardized thresholds will help to facilitate the interpretation of findings by decision-makers.

 

Abbreviations

ANC: 

antenatal care

BCC: 

behavior change communication

Ca: 

calcium

CMH: 

Commission on Macroeconomic and Health

DALY: 

disability-adjusted life year

FCHV: 

Female Community Health Volunteers

GNI: 

gross national income

ICER: 

incremental cost-effectiveness ratio

MCHIP: 

Maternal and Child Health Integrated Program

MgSO4

magnesium sulfate

MOHP: 

Ministry of Health and Population

NPR: 

nepalese rupee

PE/E: 

pre-eclampsia/eclampsia

TAG: 

Technical Advisory Group

USD: 

United States dollar

WHO: 

World Health Organization

YLD: 

years lost to disability

YLL: 

years of life lost

Declarations

Authors’ contributions

KT, DR, JB, BR, PC and CR conceived study concept and collected data for model inputs. AEL and IF designed the model and conducted subsequent analyses. IF gathered additional data from secondary sources necessary for model assumptions. IF wrote the first draft with AEL and provided revisions of the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Financial support

This work was supported by the U.S. Agency for International Development (USAID). The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all of the data in the study and had final responsibility for the decision to submit for publication.

Disclaimer

This study was made possible by the generous support of the American people through USAID. The contents are the responsibility of the authors and do not necessarily reflect the views of USAID.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of International Health, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University
(2)
Jhpiego
(3)
Jhpiego
(4)
Maternal and Child Health Integrated Program, Jhpiego
(5)
Ministry of Health, Government of Nepal

References

  1. World Health Organization: Maternal mortality. http://www.who.int/mediacentre/factsheets/fs348/en/ (2015). Accessed 14 Dec 2015.
  2. Say L, Chou D, Gemmill A, Tunçalp Ö, Moller A-B, Daniels J, Gülmezoglu AM, Temmerman M, Alkema L. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2:e323–33.View ArticlePubMedGoogle Scholar
  3. World Health Organization: Newborn death and illness. http://www.who.int/pmnch/media/press_materials/fs/fs_newborndealth_illness/en/ (2015). Accessed 14 Dec 2015.
  4. World Health Organization: Neonatal mortality. http://www.who.int/gho/child_health/mortality/neonatal_text/en/ (2015). Accessed 14 Dec 2015.
  5. Paudel D, Shrestha IB, Siebeck M, Rehfuess EA. Neonatal health in Nepal: analysis of absolute and relative inequalities and impact of current efforts to reduce neonatal mortality. BMC Public Health. 2013;13:1239.View ArticlePubMedPubMed CentralGoogle Scholar
  6. WHO, UNICEF, UNFPA, World Bank Group, and UN Population Division Maternal Mortality Estimation Inter-Agency Group: Maternal mortality in 1990–2015. 2015.
  7. Levels and Trends in Child Mortality: estimates developed by the UN inter-agency group for child mortality estimation. United Nations Children’s Fund; 2015. [Levels and Trends in Child Mortality].
  8. Trends in Maternal Mortality: 1990 to 2013 Estimates by WHO, UNICEF, UNFPAWorld Health OrganizationThe World Bank and the United Nations Population Division. Geneva 2014.
  9. Pant P, Suvedi B, Pradhan A, Hulton L, Matthews Z. Improvements in Maternal Health in Nepal: Further Analysis of the 2006 Nepal Demographic and Health Survey. Calverton: Macro International, MEASURE DHS; 2008.Google Scholar
  10. Suvedi B, Pradhan A, Barnett S, Puri M, Chitrakar S, Poudel P, Sharma S, Hulton L. Nepal Maternal Mortality and Morbidity Study 2008/2009: Summary of preliminary findings. Kathmandu, Nepal: Family Health Division, Department of Health Sciences, Ministry of Health, Government of Nepal; 2009.
  11. Ananth CV, Basso O. Impact of pregnancy-induced hypertension on stillbirth and neonatal mortality. Epidemiol Camb Mass. 2010;21:118–23.View ArticleGoogle Scholar
  12. Habli M, Levine RJ, Qian C, Sibai B. Neonatal outcomes in pregnancies with preeclampsia or gestational hypertension and in normotensive pregnancies that delivered at 35, 36, or 37 weeks of gestation. Am J Obstet Gynecol. 2007;197(406):e1–7.Google Scholar
  13. Imdad A, Jabeen A, Bhutta ZA. Role of calcium supplementation during pregnancy in reducing risk of developing gestational hypertensive disorders: a meta-analysis of studies from developing countries. BMC Public Health. 2011;11(Suppl 3):S18.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Lassi ZS, Mansoor T, Salam RA, Das JK, Bhutta ZA. Essential pre-pregnancy and pregnancy interventions for improved maternal, newborn and child health. Reprod Health. 2014;11(Suppl 1):S2.View ArticleGoogle Scholar
  15. Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L, Torloni MR. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2014;6:CD001059.Google Scholar
  16. Steer P. The epidemiology of preterm labour. BJOG Int J Obstet Gynaecol. 2005;112(Suppl 1):1–3.Google Scholar
  17. Morisaki N, Togoobaatar G, Vogel JP, Souza JP, Rowland Hogue CJ, Jayaratne K, Ota E, Mori R. WHO Multicountry Survey on Maternal and Newborn Health Research Network: risk factors for spontaneous and provider-initiated preterm delivery in high and low human development index countries: a secondary analysis of the World Health Organization Multicountry survey on maternal and newborn health. BJOG Int J Obstet Gynaecol. 2014;121(Suppl 1):101–9.View ArticleGoogle Scholar
  18. Jana N, Dasgupta S, Das AK, Santra D, Samanta B. Experience of a low-dose magnesium sulfate regimen for the management of eclampsia over a decade. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 2013;122:13–7.View ArticleGoogle Scholar
  19. Chaudhary P. Eclampsia: before and after magnesium sulphate. JNMA J Nepal Med Assoc. 2005;44:124–8.PubMedGoogle Scholar
  20. Shilva N, Saha SC, Kalra J, Prasad R. Safety and efficacy of low-dose MgSO4 in the treatment of eclampsia. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 2007;97:150–1.View ArticleGoogle Scholar
  21. Thapa K, Jha R. Magnesium sulphate: a life saving drug. JNMA J Nepal Med Assoc. 2008;47:104–8.PubMedGoogle Scholar
  22. Firoz T, Sanghvi H, Merialdi M, von Dadelszen P. Pre-eclampsia in low and middle income countries. Best Pract Res Clin Obstet Gynaecol. 2011;25:537–48.View ArticlePubMedGoogle Scholar
  23. Dhakal G, Subedi M, Paudel K. Magnesium sulphate in management of severe pre-eclampsia and eclampsia. J Nepal Health Res Counc. 2012;10:113–7.PubMedGoogle Scholar
  24. Prakash KC, Neupane S. Cesarean deliveries among Nepalese mothers: changes over time 2001–2011 and determinants. Arch Gynecol Obstet. 2014;289:421–7.View ArticlePubMedGoogle Scholar
  25. Hofmeyr GJ, Belizán JM, von Dadelszen P. Calcium and Pre-eclampsia (CAP) Study Group: low-dose calcium supplementation for preventing pre-eclampsia: a systematic review and commentary. BJOG Int J Obstet Gynaecol. 2014;121:951–7.View ArticleGoogle Scholar
  26. Patrelli TS, Dall’asta A, Gizzo S, Pedrazzi G, Piantelli G, Jasonni VM, Modena AB. Calcium supplementation and prevention of preeclampsia: a meta-analysis. J Matern-Fetal Neonatal Med. 2012;25:2570–4.View ArticlePubMedGoogle Scholar
  27. World Health Organization: WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. Geneva: World Health Organization; 2011.
  28. Shmueli A, Meiri H, Gonen R. Economic assessment of screening for pre-eclampsia. Prenat Diagn. 2012;32:29–38.View ArticlePubMedGoogle Scholar
  29. Zakiyah N, Postma MJ, Baker PN, van Asselt ADI. IMPROvED Consortium: pre-eclampsia diagnosis and treatment options: a review of published economic assessments. PharmacoEconomics. 2015;33:1069–82.View ArticlePubMedPubMed CentralGoogle Scholar
  30. Simon J, Gray A, Duley L. Magpie Trial Collaborative Group: cost-effectiveness of prophylactic magnesium sulphate for 9996 women with pre-eclampsia from 33 countries: economic evaluation of the Magpie Trial. BJOG Int J Obstet Gynaecol. 2006;113:144–51.View ArticleGoogle Scholar
  31. Blackwell SC, Tomlinson MW, Berman S, Redman ME, Hassan SS, Berry SM, Hallak M, Sorokin Y, Cotton DB. The use of magnesium sulfate to prevent seizures in the pre-eclamptic gravida: a cost-effectiveness analysis. Prenat Neonatal Med. 2001;6:310–7.Google Scholar
  32. Meads CA, Cnossen JS, Meher S, Juarez-Garcia A, ter Riet G, Duley L, Roberts TE, Mol BW, van der Post JA, Leeflang MM, Barton PM, Hyde CJ, Gupta JK, Khan KS. Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess Winch Engl. 2008;12:1–270.Google Scholar
  33. United Nations Field Coordination Office: UNDAF District Profile: Dailekh. 2012.
  34. Pre-eclampsia/eclampsia situation in nepal the need for protein test in urine during pregnancy. K4Health: Baltimore; 2011.
  35. Nepal Demographic and Health Survey 2011. Calverton: Ministry of Health and Population, New ERA, and ICF International; 2012.
  36. OANDA: currency converter: NPR to USD. http://www.oanda.com/currency/converter/ (2015). Accessed 14 Dec 2015.
  37. Fox-Rushby JA, Hanson K. Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. Health Policy Plan. 2001;16:326–31.View ArticlePubMedGoogle Scholar
  38. Chuni N, Khanna S. Risk factors in relation to eclampsia in Nepal. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 2004;87:159–60.View ArticleGoogle Scholar
  39. Global Health Observatory. World Health Organization, Geneva. 2015. http://apps.who.int/gho/data/node.main. Accessed 14 Dec 2015.
  40. World Health Organization: global burden of disease 2004 update: disability weights for diseases and conditions. 2004.
  41. Borghi J, Ensor T, Neupane BD, Tiwari S. Coping with the burden of the costs of maternal health. Nepal Safer Mother Proj Part HMGN Safe Mother Programme Publ Place Publ 2004.
  42. Ministry of Labour and Transport: Notice of Government of Nepal (GoN). Chicago: Nepal Gazette; 2008. p. 1–3.
  43. Upreti SR, Baral SC, Tiwari S, Elsey H, Aryal S, Tandan M, et al. Rapid assessment of the demand side financing schemes: AAMA Programme and 4ANC [Internet]. Kathmandu, Nepal: Ministry of Health and Population; Nepal Health Sector Support Programme and HERD; 2012. http://www.nhssp.org.np/health_financing/DSF-RA-FINAL%20with%20Cover.pdf.
  44. The World Bank Group: GDP per capita (current US$). http://data.worldbank.org/indicator/NY.GDP.PCAP.CD/countries (2015). Accessed 14 Dec 2015.
  45. World Health Organization: Threshold values for intervention cost-effectiveness by Region. http://www.who.int/choice/costs/CER_levels/en/ (2015). Accessed 14 Dec 2015.
  46. Choudhary P. Eclampsia: a hospital based retrospective study. Kathmandu Univ Med J KUMJ. 2003;1:237–41.PubMedGoogle Scholar
  47. Laxminarayan R, Chow J, Shahid-Salles SA. Intervention cost-effectiveness: overview of main messages. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P, editors. Disease control priorities in developing countries. 2nd ed. Washington: World Bank; 2006.Google Scholar

Copyright

© The Author(s) 2016

Advertisement